OncoSil Medical (ASX:OSL) - Managing Director & CEO, Nigel Lange
Managing Director & CEO, Nigel Lange
Source: OncoSil Medical
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • OncoSil Medical (OSL) places its shares in a trading halt pending the release of a capital raising announcement
  • The medical technology company’s shares will remain in the halt until the earlier of April 29 or when the announcement is released to the market
  • In mid-April, OncoSil reported the first commercial treatment of pancreatic cancer regarding its flagship device in Europe
  • The OncoSil device implants a pre-determined dose of beta radiation directly into the cancerous tissue via endoscopic ultrasound guidance
  • Shares in OncoSil last traded at 6.1 cents on April 26

OncoSil Medical (OSL) has placed its shares in a trading halt pending the release of a capital raising announcement.

The medical technology company’s shares will remain in the halt until the earlier of April 29 or when the announcement is released to the market.

OncoSil is yet to disclose how much it intends to raise or what it will use the funds for once received.

In mid-April, OncoSil reported the first commercial treatment of pancreatic cancer regarding its flagship OncoSil device in Europe.

The procedure was performed at the Hospital Universitario de Fuenlabrada in Madrid, Spain.

CEO and Managing Director Nigel Lange said this is an “important milestone” with plans underway to work with other hospitals to maximise treatment.

The company’s namesake device is a brachytherapy (cancer treatment) device that implants a pre-determined dose of beta radiation directly into the cancerous tissue via injection under endoscopic ultrasound guidance.

The ultrasound then uses high-frequency sound waves to produce detailed images of the lining and walls of specific organs, with the beta particles travelling a short distance to the tissue causing the damage.

The procedure helps locate the cancerous cells and then chemotherapy destroys them.

Shares in OncoSil last traded at 6.1 cents on April 26. The company has a $48.33 million market cap.

OSL by the numbers
More From The Market Herald
The Market Herald Video

" Aurora Energy Metals (ASX:1AE) defies market pressures with solid ASX debut 

Aurora Energy Metals (ASX:1AE) continues to defy market pressures on day two of trading, with shares up…
Invictus Energy (ASX:IVZ) - Non Executive Chairman, Dr Stuart Lake

" Invictus Energy (ASX:IVZ) enters trading halt for capital raise

Invictus Energy (ASX:IVZ) has placed its shares in a trading halt pending the release of a…
Australian Vanadium (ASX:AVL) - Managing Director, Vincent Algar

" Australian Vanadium (ASX:AVL) enters mid-week trading halt

Australian Vanadium (ASX:AVL) has entered a mid-week trading halt pending an upcoming capital raising.
The Market Herald Video

" Capital raising and IPO news: Orcoda (ASX:ODA) raises for vehicle buy

Logistic tech business Orcoda (ASX:ODA) raised just over $1.25 million through a placement and share purchase plan to…